CagriSema vs HGH Fragment 176-191.

CagriSema is a fixed-combination injectable investigational obesity therapeutic developed by Novo Nordisk that co-formulates two long-acting peptide analogues in a single once-weekly subcutaneous injection: cagrilintide, a long-acting amylin receptor agonist (analogue of the pancreatic hormone amylin), and semaglutide, a GLP-1 (glucagon-like peptide-1) receptor agonist already marketed for diabetes and obesity. It pairs the same semaglutide molecule found in Ozempic and Wegovy with a novel amylin analogue, making it the first amylin-plus-GLP-1 dual-hormone combination to reach late-stage clinical development for weight management.

HGH Fragment 176-191 is a synthetic peptide corresponding to the final 16 amino acids (residues 176 to 191) of the C-terminal region of human growth hormone. It derives from the observation that this domain appears to carry GH's fat-metabolizing (lipolytic) activity while lacking the growth-promoting and insulin-antagonizing actions of the whole hormone. It is closely related to, but distinct from, AOD-9604, a modified analog in which a tyrosine residue is added to the N-terminus (developed under the name Anti-Obesity Drug 9604). The plain 176-191 fragment itself is a research-only compound with almost no dedicated clinical data.

The two components act on complementary appetite-regulating pathways. Semaglutide is a GLP-1 receptor agonist that slows gastric emptying and signals through hypothalamic and brainstem circuits to reduce hunger and increase satiety. Cagrilintide is an amylin analogue that engages amylin and calcitonin-family receptors, also acting on the area postrema and hypothalamus to promote satiation and reduce food intake; amylin signaling is thought to modulate leptin sensitivity and meal termination through a partly distinct mechanism from GLP-1. The rationale is that combining the two yields additive or complementary reductions in energy intake beyond either agent alone.

The proposed mechanism is stimulation of lipolysis, the breakdown of stored triglycerides, along with reduced fat synthesis in adipose tissue, reproducing the fat-reducing effect of GH's C-terminus without activating the GH receptor to raise IGF-1 or impair glucose handling. Work on the analog AOD-9604 implicated the beta-3-adrenergic pathway in this effect. The mechanism is characterized mainly in mouse and in vitro models, and how faithfully the unmodified 176-191 fragment reproduces it in humans is not established.

Unlike most "research peptides," CagriSema has substantial human Phase 3 data from the REDEFINE program. In REDEFINE 1 (Garvey et al., NEJM 2025; 68 weeks, ~3,400 adults with obesity/overweight without diabetes), CagriSema produced roughly 20% mean body-weight loss versus semaglutide alone, cagrilintide alone, and placebo. In REDEFINE 2 (Davies et al., NEJM 2025), conducted in adults with overweight/obesity and type 2 diabetes, CagriSema reduced body weight and HbA1c versus placebo, though weight loss in the diabetes population was more modest, consistent with the general pattern for incretin therapies. REDEFINE 5 (Yamauchi et al., Lancet Diabetes & Endocrinology 2026) evaluated it versus semaglutide alone in Japan and Taiwan. Importantly, in the open-label head-to-head REDEFINE 4 trial, CagriSema (~23% weight loss on the efficacy estimand) did NOT meet its primary endpoint of non-inferiority versus tirzepatide (Zepbound, ~25.5%), a notable negative result that tempers claims of clear superiority over existing dual/incretin therapies.

Almost all supportive data come from the modified analog AOD-9604 rather than from 176-191 itself. Heffernan et al., in Endocrinology (2001, PMID 11713213), showed that AOD9604 reduced body weight and increased lipolysis in obese mice and that the effect disappeared in beta-3-adrenergic-receptor knockout mice, implicating that pathway. That was a rodent study using genetically obese and knockout strains, with short treatment periods and body-weight and tissue endpoints rather than clinical outcomes. Its central finding, dependence on a receptor whose contribution to human fat metabolism is far smaller than in rodents, is itself a reason to doubt direct translation. AOD-9604 was later carried into human obesity trials but did not produce clinically meaningful weight loss beyond placebo and was not approved as a drug. The program, run by an Australian sponsor, was discontinued after the larger placebo-controlled trial failed to separate from placebo on weight, which is the endpoint that matters for an anti-obesity indication. The compound was subsequently repositioned toward non-pharmaceutical uses, and a separate strand of published work examined intra-articular AOD9604 in a rabbit osteoarthritis model rather than obesity, which says nothing about systemic fat loss. For the unmodified 176-191 fragment specifically there is essentially no controlled human evidence, and its reputation is extrapolated from AOD-9604 data. The tyrosine added to the N-terminus of AOD-9604 was a deliberate stability modification, so the two molecules are not interchangeable, and no published head-to-head comparison establishes that the plain fragment behaves like the analog in people. The contrast with full-length somatropin is instructive: recombinant GH has approved indications, product labeling, decades of registry data, and a well-mapped metabolic profile, while the fragment has none of that. There are no human pharmacokinetic data for 176-191, no bioavailability data, no dose-ranging work, no imaging-based body-composition endpoints, and no long-term study of any kind.

The most common adverse events in the REDEFINE trials were gastrointestinal: nausea, vomiting, diarrhea, and constipation, consistent with the known class effects of GLP-1 receptor agonists and amylin analogues; these were generally mild-to-moderate and most frequent during dose escalation. As with other GLP-1-based therapies, label-level concerns for the class include gallbladder events, pancreatitis risk signals, and a boxed thyroid C-cell tumor warning carried by semaglutide products (based on rodent data). Long-term safety, durability after discontinuation, and outcomes in broader real-world populations remain incompletely characterized because the compound is still investigational and only recently filed for approval. No legitimate medical use exists outside clinical trials and (pending) regulatory approval, and gray-market "research" cagrilintide/semaglutide products carry purity, sterility, and dosing-error risks.

In its trials the analog AOD-9604 was generally well tolerated over short periods, with headache and mild edema among the reported effects, but the plain 176-191 fragment has no comparable human safety record of its own. Long-term safety is unknown. The theoretical selling point of the fragment, that it separates GH's lipolytic action from the growth-promoting and insulin-antagonizing actions of the whole hormone, has never been confirmed in a controlled human study, so the assumption that it avoids GH's metabolic liabilities remains an assumption rather than a finding. Full-length growth hormone reliably raises IGF-1 and can worsen glucose tolerance and cause fluid retention, carpal tunnel symptoms, and arthralgia. Whether a C-terminal fragment is genuinely free of those effects at meaningful exposure is untested, and no study has measured IGF-1 or glucose handling during sustained exposure to the fragment. Because the peptide is administered by injection, the usual injection risks apply: local reactions, infection from non-sterile technique or non-sterile product, and immune response to a foreign fragment. Nothing published characterizes immunogenicity for this sequence. Injectable material sold online as Fragment 176-191 is unregulated research-grade product of uncertain identity and purity, frequently supplied without a certificate of analysis or with one that cannot be traced to the vial in hand, and independent testing of this market has found mislabeled and contaminated product. A proper trial would require fasting glucose and insulin, IGF-1, and lipid monitoring, together with sterility and endotoxin testing of the material, none of which happens outside a regulated setting. The safety of the fragment itself remains largely uncharacterized.

CagriSema is investigational and not approved by the FDA or EMA as of mid-2026; Novo Nordisk submitted a U.S. New Drug Application for chronic weight management on December 18, 2025, with a regulatory decision anticipated in late 2026. Its individual components have separate statuses: semaglutide is FDA-approved (e.g., Wegovy, Ozempic), while cagrilintide alone is not approved.

HGH Fragment 176-191 is not an approved drug and is sold as research-use-only. The related AOD-9604 was investigated for obesity, failed to reach approval as a pharmaceutical, and was subsequently pursued as a food and cosmetic ingredient in some markets; neither has FDA approval as a weight-loss medicine. GH fragments of this type are prohibited in sport by WADA.